Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.16 USD
Change Today -0.0099 / -5.88%
Volume 37.9K
VASO On Other Exchanges
As of 3:06 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

vasomedical inc (VASO) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/17/14 - $0.25
52 Week Low
12/15/14 - $0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VASOMEDICAL INC (VASO)

Related News

No related news articles were found.

vasomedical inc (VASO) Related Businessweek News

No Related Businessweek News Found

vasomedical inc (VASO) Details

Vasomedical, Inc. designs, manufactures, markets, and supports enhanced external counterpulsation (EECP) therapy systems, ambulatory monitoring systems, and other medical equipment to physician and hospitals in the United States and internationally. The company operates through three segments, Sales Representation, Equipment, and Information Technology (IT). Its EECP technology is a non-invasive and outpatient therapy for the treatment of cardiovascular diseases, as well as angina, cardiogenic shock, acute myocardial infarction, and congestive heart failure. The company also develops wireless multi-parameter patient monitoring systems; and distributes GE Healthcare’s diagnostic imaging products, as well as offers in-service and training support for the EECP systems. In addition, it is involved in the healthcare IT business. Vasomedical, Inc. was founded in 1987 and is headquartered in Plainview, New York.

218 Employees
Last Reported Date: 03/30/15
Founded in 1987

vasomedical inc (VASO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $275.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $185.0K
Senior Vice President, Director and Chief Exe...
Total Annual Compensation: $600.0K
Vice President of Finance and Controller
Total Annual Compensation: $160.0K
Compensation as of Fiscal Year 2014.

vasomedical inc (VASO) Key Developments

Vasomedical, Inc. Announces Relocation of Corporate Office

Vasomedical Inc. has announced the relocation of its corporate office to Plainview, New York. In addition to the headquarters, this facility at Plainview, Long Island will also house the operations of Vasomedical Solutions Inc. and the New York offices of NetWolves Network Services, both of which are wholly owned subsidiaries of Vasomedical Inc. The relocation takes places upon the expiration of the lease of the company's Westbury, NY facility, which has housed the company's headquarters and main operations for the last twenty years. The consolidated use of the new facility, together with the reduced need for space as the company's EECP(R) systems manufacturing has been transferred to its subsidiary located in China, results in improved operational efficiency and significant cost savings. All communications to Vasomedical Inc. as well as to Vasomedical Solutions and NetWolves Network Services New York offices should be addressed to 137 Commercial Street, Suite 200, Plainview, NY 11803, USA.

Vasomedical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Vasomedical Inc. reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue increased $3.0 million, or 38% year-over-year, to $10.9 million compared to $7.9 million for the same period of 2014. The increase was principally due to $2.8 million in revenue from recently acquired NetWolves operations. Net income was $0.2 million, a significant improvement compared to the net loss of $0.2 million for the three months ended June 30, 2014. This improvement is principally due to an increase in gross profit and a decrease in SG&A costs in the Sales Representation segment and lower costs in the Equipment segment. For the six months, the company reported net loss of $0.062 million compared to a net loss of $1.22 million, or $0.01 loss per share, for the same period ended June 30, 2014. Total revenues of $18.3 million, compared to $14.96 million for the same period ended June 30, 2014.

Vasomedical Inc. to Report Q2, 2015 Results on Aug 20, 2015

Vasomedical Inc. announced that they will report Q2, 2015 results at 11:00 AM, US Eastern Standard Time on Aug 20, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VASO:US $0.16 USD -0.0099

VASO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $37.28 USD -0.345
Koninklijke Philips NV €22.25 EUR -0.17
Siemens AG €84.89 EUR -1.02
Toshiba Corp ¥337.30 JPY -11.40
View Industry Companies

Industry Analysis


Industry Average

Valuation VASO Industry Range
Price/Earnings 10.9x
Price/Sales 0.7x
Price/Book 3.2x
Price/Cash Flow 11.1x
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASOMEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at